Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban



Status:Completed
Conditions:Cardiology, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:9/8/2018
Start Date:July 15, 2017
End Date:September 15, 2017

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
To estimate the real-world rates of recurrent Venous thromboembolism (VTE), major bleeding
and all-cause mortality in patients with Cancer-associated thrombosis (CAT) treated with
rivaroxaban


Inclusion Criteria:

- Adult patients (≥18 years-of-age) with active cancer

- Patient with at least one index venous thromboembolism (VTE )

- ≥6-months of continuous eligibility prior to the index VTE event (baseline period).

- Newly initiated on rivaroxaban

Exclusion Criteria:

- Patients with any medical claim for Deep vein thrombosis (DVT) or Pulmonary embolism
(PE) during the 6 months pre-index date

- Patients with prescription claim for anticoagulation therapy during the 6-month
pre-index VTE period
We found this trial at
1
site
US database
768 Bedford Avenue
New York, New York 10001
?
mi
from
New York, NY
Click here to add this to my saved trials